Achillion To Webcast September 27th Analyst Day

NEW HAVEN, Conn., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it will host a live webcast of its inaugural Analyst Day on Thursday, September 27, 2012 beginning at 1:00 p.m. Eastern Time.

The senior management team, led by Michael Kishbauch, President and Chief Executive Officer of Achillion, will review Achillion's hepatitis C (HCV) programs and future clinical development plans. In addition, presentations are expected to be made by Alan Perelson, Ph.D., Senior Fellow, Los Alamos National Laboratory; Douglas Dieterich, M.D., Professor of Medicine, Liver Diseases, Mount Sinai School of Medicine; and Fred Poordad, M.D., Chief Medical Officer of the Texas Liver Institute / Alamo Medical Research; with Q&A sessions facilitated by Kurt Graves, Director of Achillion, and Chairman, President and Chief Executive Officer of Intarcia Therapeutics.

The webcast will be accessible from the Investor Relations page on the Company's website at . A replay of the webcast will be archived on the Company's website beginning approximately two hours following the live event.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit or call 1-203-624-7000.
CONTACT: Company Contact:         Glenn Schulman         Achillion Pharmaceuticals, Inc.         Tel. (203) 624-7000                  Media:         Christin Culotta Miller         Ogilvy PR         Tel. (646) 229-5178                  Investors:         Mary Kay Fenton         Achillion Pharmaceuticals, Inc.         Tel. (203) 624-7000                  Investors:         Seth Lewis         The Trout Group, LLC         Tel. (646) 378-2952